Variable name;level;Overall;Yes;No;p;test
;n;262;83;179;;
Age;[0 -30);63 (24.0);16 (19.3);47 (26.3);0.219;
;[30 -35);119 (45.4);35 (42.2);84 (46.9);;
;[35 -40);76 (29.0);31 (37.3);45 (25.1);;
;40+;4 (1.5);1 (1.2);3 (1.7);;
Age (mean);;32.7 (3.7);33.4 (3.6);32.4 (3.8);0.058;
Number of children;0;177 (67.6);55 (66.3);122 (68.2);0.932;
;1;53 (20.2);17 (20.5);36 (20.1);;
;More than 1;32 (12.2);11 (13.3);21 (11.7);;
BMI;<18.5;16 (6.3);11 (13.6);5 (2.9);0.011;
;25-29.9;46 (18.0);12 (14.8);34 (19.5);;
;>=30;12 (4.7);3 (3.7);9 (5.2);;
;18.5-24.9;181 (71.0);55 (67.9);126 (72.4);;
BMI (mean);;22.0 [20.3, 24.5];21.6 [19.9, 24.4];22.4 [20.3, 24.8];0.103;nonnorm
Treatment center;Curie Paris;168 (64.1);52 (62.7);116 (64.8);NaN;
;Curie St Cloud;94 (35.9);31 (37.3);63 (35.2);;
;Others;0 (0.0);0 (0.0);0 (0.0);;
Genetic Analysis;No;55 (21.0);21 (25.3);34 (19.0);0.316;
;Yes;207 (79.0);62 (74.7);145 (81.0);;
Hereditary predisposition;No;159 (77.6);46 (74.2);113 (79.0);0.563;
;Yes;46 (22.4);16 (25.8);30 (21.0);;
Inflammatory BC;No;260 (99.2);83 (100.0);177 (98.9);0.838;
;Yes;2 (0.8);0 (0.0);2 (1.1);;
Clinical Tumor size (mm);;32.0 (20.2);21.8 (13.9);36.6 (20.9);<0.001;
Clinical N stage (TNM);N0;165 (63.2);61 (74.4);104 (58.1);NaN;
;N1;96 (36.8);21 (25.6);75 (41.9);;
;N2;0 (0.0);0 (0.0);0 (0.0);;
;N3;0 (0.0);0 (0.0);0 (0.0);;
SBR grade;Grade I;11 (4.2);3 (3.6);8 (4.5);0.623;
;Grade II;96 (36.8);34 (41.0);62 (34.8);;
;Grade III;154 (59.0);46 (55.4);108 (60.7);;
Histological type;NST;249 (95.0);76 (91.6);173 (96.6);0.204;
;Lobular;6 (2.3);3 (3.6);3 (1.7);;
;Others;7 (2.7);4 (4.8);3 (1.7);;
Neoajuvant chemotherapy;No;118 (45.0);77 (92.8);41 (22.9);<0.001;
;Yes;144 (55.0);6 (7.2);138 (77.1);;
Chemotherapy setting;NAC;144 (55.0);6 (7.2);138 (77.1);NaN;
;Adjuvant;118 (45.0);77 (92.8);41 (22.9);;
;NAC and adjuvant;0 (0.0);0 (0.0);0 (0.0);;
;Chemotherapy without surgery;0 (0.0);0 (0.0);0 (0.0);;
;No;0 (0.0);0 (0.0);0 (0.0);;
Fertility preservation discussion;No;3 (1.1);1 (1.2);2 (1.1);1.000;
;Yes;259 (98.9);82 (98.8);177 (98.9);;
